Get the Stockscreener App
29.17
1.33%
-0.32
Beam Therapeutics Inc stock is traded at $29.17, with a volume of 736.40K.
It is down -1.33% in the last 24 hours and down -8.35% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
See More
Previous Close:
$29.49
Open:
$29.75
24h Volume:
736.40K
Relative Volume:
0.36
Market Cap:
$3.00B
Revenue:
$164.01M
Net Income/Loss:
$-65.04M
P/E Ratio:
-42.46
EPS:
-0.687
Net Cash Flow:
$-383.84M
1W Performance:
-11.39%
1M Performance:
-8.35%
6M Performance:
+5.77%
1Y Performance:
+62.65%
1-Day Range:
$28.75
$30.00
1-Week Range:
$28.64
$32.56
52-Week Range:
$15.60
$36.44
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
29.16 | 3.03B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
438.91 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.36 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.36 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.32 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.08 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Canaccord Genuity | Buy |
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics (Nasdaq: BEAM) shareholders approve directors, auditor and pay - Stock Titan
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics Inc (BEAM) Stock Price, Quote, News & History - Benzinga
Beam Therapeutics (BEAM) director receives 19,676-share option grant - Stock Titan
Beam Therapeutics (BEAM) director receives stock options grant for 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) grants 19,676 stock options to director - Stock Titan
Beam Therapeutics (BEAM) director receives stock options on 19,676 shares - Stock Titan
Beam Therapeutics (BEAM) awards stock options to director Chirfi - Stock Titan
Beam Therapeutics (BEAM) awards director Graham Cooper 19,676 options - Stock Titan
BEAM Stock Price, Quote & Chart - ChartMill
Bethany Cavanagh (Beam Therapeutics) sells $79,688 in BEAM stock - Investing.com
Wells Fargo Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Beam Therapeutics CEO Evans sells $739k in stock - Investing.com
BEAM Technical Analysis & Stock Price Forecast - Intellectia AI
Beam Therapeutics Stock Hits Day Low of $28.80 Amid Price Pressure - Markets Mojo
Beam Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
BEAM Technical Analysis | Trend, Signals & Chart Patterns | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Technical Reactions to BEAM Trends in Macro Strategies - Stock Traders Daily
Draft FDA guidance could be a boon for gene therapy developers - Seeking Alpha
Beam Therapeutics eyes sickle cell BLA as Alpha-1 gene-editing program advances - MSN
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - AOL.com
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - Quantisnow
Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD - Yahoo Finance
Gene Editing Sector Gains Momentum with Key Players CRISPR and Beam - Intellectia AI
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? - The Motley Fool
What Were the Key Highlights from Beam's RBC Conference Presentation - Kavout
ADAR1 Capital Management, LLC's Beam Therapeutics Inc(BEAM) Holding History - GuruFocus
Trading the Move, Not the Narrative: (BEAM) Edition - Stock Traders Daily
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com - Investing.com South Africa
CCORF Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $75 - Moomoo
H.C. Wainwright Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $80 - Moomoo
Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International ConferenceSlideshow - Seeking Alpha
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances - Barchart.com
BEAM: Lead gene editing programs advance toward approval with strong efficacy, safety, and payer value - TradingView
Beam Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock - Insider Monkey
In Vivo Gene Editing Market is expected to Hit US$ 37.75 Billion - openPR.com
10 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
Beam Therapeutics (BEAM) Is Down 12.0% After Narrowing Losses And Positive BEAM-302 Data Update – Has The Bull Case Changed? - Sahm
Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus - Yahoo Finance
Beam Therapeutics (BEAM) Advances Phase 1/2 Trial for AAT Deficiency - GuruFocus
Verve Therapeutics : VERV - 24/7 Wall St.
Beam Therapeutics presents AATD gene therapy trial data at ATS - Investing.com UK
Beam Therapeutics presents AATD gene therapy trial data at ATS By Investing.com - Investing.com Australia
Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
One-time gene-editing AATD therapy BEAM-302 seeks accelerated FDA path - Stock Titan
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
2.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):